145 results on '"Galetta, D."'
Search Results
2. EP01.01-12 Binge-Watching Frequency and Tobacco Use in Adolescents: Data from “Blaam Smoke-Free Movie” Program
3. MA07.09 Adapted Physical Activity (AMAti) Program for Lung Cancer Patients Realized by WALCE (Women Against Lung Cancer in Europe)
4. EP04.01-02 Volatile Organic Compounds in Exhaled Breath as Biomarkers for Lung Cancer. A Screening-Based Study in High-Risk Participants
5. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1
6. P2.10-05 Circulating CD3+CD56+ Cells as a Biomarker for Immunotherapy in SCLC.
7. EP16.03-040 Biomarkersatlas.com: the Italian NSCLC Precision Medicine Knowledge Data Base
8. P2.14-02 TP53 Mutations Affect Sensitivity to Lorlatinib in ROS1 Positive NSCLC: Final Results of the PFROST Trial
9. 1019P Pattern of clinical activity of anticancer vaccine OSE2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO) in phase III Atalante-1 randomized trial
10. EP08.02-048 Crizotinib in ROS1+NSCLC: Long-term OS Analysis in Patients with Brain Metastases Included in the Phase II METROS Trial
11. EP08.02-101 Real-world Data from KRAS-mutant Advanced NSCLC: the ATLAS Multicenter Cohort Study
12. EP02.04-001 Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-Positive NSCLC: ALNEO Phase II Trial (GOIRC-01-2020)
13. 125P Radiomic signature from baseline CT Scan to predict initial response to treatment in advanced/unresectable pleural mesothelioma: Preliminary data
14. LBA47 Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO): Final results of phase III Atalante-1 randomised trial
15. Prognostic value of PET parameters in patients with pleomorphic lung cancer: Results from a single institution
16. 104P Fast progression in high PD-L1 NSCLC treated with pembrolizumab in first-line: A prognostic scoring system based on clinical features
17. Upfront pembrolizumab as an effective treatment start in patients with PD-L1 ≥ 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis
18. P75.21 Impact of Diagnosis and Treatment of Concurrent Infections during Immunotherapy in Advanced Lung Cancer: A Retrospective Cohort Study
19. P75.14 Gender-Related Safety and Outcome in Advanced NSCLC Patients Treated with Immune Checkpoint-Inhibitors. A Real-World Experience
20. P78.12 A Rare Case of Dermatomyositis as Late Immune-Related Toxicity During Anti-PD1 Treatment for Advanced Lung Cancer
21. FP06.04 Psychological Distress in Outpatients with Lymphoma, Lung and Breast Cancer during COVID-19 pandemic
22. P40.01 Tobacco use in Adolescence and Associated Factors: Products, School, Family, Peers and Movies in Pandemic Period
23. 1260MO Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial
24. Baseline neutrophil-to-lymphocyte ratio and PD-L1 expression level or LDH value may predict outcome of patients with high PD-L1 advanced non-small cell lung cancer treated with first-line pembrolizumab
25. Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: A multicenter study
26. Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study
27. Secondary ROS1 mutations and lorlatinib sensitivity in crizotinib-refractory ROS1 positive NSCLC: Results of the prospective PFROST trial
28. MA10.05 Breath Analysis: New Key-Challenges for Early Detection of Lung and Pleural Neoplasms
29. P2.01-74 Clinical-Pathological Features and Outcome of Patients with Oral Metastases from Lung Cancer: A Multicenter Retrospective Study
30. EP1.01-81 Resection of Tumors with Carinal Involvement After Induction Therapy
31. EP1.01-44 Early and Long-Term Results of Tracheal Sleeve Pneumonectomy for Lung Cancer After Induction Therapy
32. P1.15-11 Intrathoracic Neurogenic Tumors: Clinical, Pathological, and Long-Term Outcomes
33. The elderly patient individualized chemotherapy (EPIC) trial, a study for an aged population of non-small cell lung cancer
34. EP1.04-38 A Case of Lichenoid Reaction as Late and Uncommon Immune-Related Skin Toxicity During Nivolumab Treatment
35. Prognostic role of RLF/MYCL1 and circPVT1 in SCLC
36. P1.16-09 Post-Progression Outcomes After Pembrolizumab in Patients with NSCLC and High PD-L1 Expression: Real-World Data from a European Cohort
37. P2.04-07 Surgical Resection of Advanced Lung Cancer After a Response to EGFR-TKI and/or Immunotherapy: A Single Institution Experience
38. EP1.01-56 Co-Presentation of Adenocarcinoma and Squamous Cell Lung Carcinoma Harbouring ALK Rearrangement in Different Sites
39. P1.14-26 ALK Fusion Variant Detection by Targeted RNA-Seq in TKIs Treated ALK-Positive Lung Adenocarcinoma
40. P1.15-01 Prognostic Factors and Long-Term Outcomes After Pulmonary Metastasectomy from Renal Cell Carcinoma
41. P1.14-03 Molecular Determinants for Lorlatinib Activity in ROS1 Positive NSCLC: Results of the Prospective PFROST Trial
42. P1.04-58 Uncovering the Tumor Microenvironment of KRAS-Driven Lung Adenocarcinoma: The Link Between Th17 Signaling and B Cell
43. P2.10-06 Smoking Prevalence and Perceptions Among Healthcare Professionals: A Survey in an Italian Clinical Cancer Centre
44. MA06.11 CT-Guided Percutaneous Radiotracer Localization and Resection of Indistinct/Small Pulmonary Lesions
45. EP1.17-19 Robotic-Assisted Thoracic Surgery for Early Stage Lung Cancer: Ten Years' Single Institution Experience
46. P2.01-15 Phase II Single Arm Study of CABozantinib in Non-Small Cell Lung Cancer Patients with MET Deregulation (CABinMET)
47. Pembrolizumab frontline monotherapy in patients with NSCLC and high PD-L1 expression: Real-world data from a European Cohort with focus on subgroups of interest
48. P1.01-59 Expanding Access to Large-Scale Genomic Mutational Analyses for Patients with Advanced NSCLC in Italy
49. P2.04-14 NLR, dNLR and PLR as Possible Predictive Markers in Patients with NSCLC Treated with ICI
50. EP1.01-01 Atrial Resection Without Cardiopulmonary Bypass for Lung Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.